Florida Hospital Cancer Institute Community Clinical Oncology Program

描述（由申请人提供）：基督复临安息日会医院系统在10个州经营37家医院。在佛罗里达州中部，佛罗里达医院系统有六个医院校区（将参与FHCI-CCOP申请），它们在一个许可证下运作。佛罗里达七家医院系统的旗舰医院是位于奥兰治县奥兰多的佛罗里达南医院（FH）。佛罗里达南医院（FH）提供全面的服务，包括内科肿瘤学、放射肿瘤学、儿科肿瘤学、骨髓移植、外科肿瘤学、神经肿瘤学和妇科肿瘤学。佛罗里达州中部的其他五家医院位于邻近的奥塞洛县和塞米诺尔县。第七家医院佛罗里达医院纪念医疗中心（MMC）位于沃卢西亚县。MMC也归基督复临医疗集团所有，但拥有单独的许可证。佛罗里达医院癌症研究所（FHCI）的成立是为了协调FH系统中所有的癌症活动。Lee Zehngebot博士领导FHCI的临床活动已有20多年。Zehngebot博士是FHCI内一项成功临床试验的设计师。该项目获得了国家级奖项和认可。FHCl的研究部在合作小组试验和药物试验方面有着悠久的历史。在过去的一年里，我们准备向CCOP项目过渡，FHCI注册了相当于56个治疗学分和54.8个癌症控制学分的CCOP学分，其中大部分学分是自2011年1月以来积累的。此外，FHCl的集水区包括西班牙裔人口超过40%和非洲裔人口超过20%的县。虽然肿瘤登记数据显示只有11%的西班牙裔和8.5%的非洲裔美国人，但临床试验登记显示13%的西班牙裔和10%的非洲裔美国人。FH系统中的上述六家医院以及另一家MMC希望成为CCOP。我们将CCOP奖项视为进一步整合我们癌症临床试验和研究项目的基石。CCOP奖将允许FHCI在佛罗里达州中部社区的地理和范围上扩大其临床试验工作。

DESCRIPTION (provided by applicant): The Seventh Day Adventist Hospital System operates 37 hospitals in 10 states. In Central Florida, the Florida Hospital System has six hospital campuses (that will be participating in the FHCI-CCOP application) that bill under one license. The flagship hospital of the seven Florida Hospital System is Florida Hospital South (FH) located in Orlando, Orange County. Florida Hospital South (FH) offers a full array of services including medical oncology, radiation oncology, pediatric oncology, bone marrow transplantation, surgical oncology, neuro-oncology, and gynecologic oncology. The other five hospitals in Central Florida are located in the neighboring Oscelo and Seminole counties. A seventh hospital Florida Hospital Memorial Medical Center (MMC) is located in Volusia County. MMC is also owned by Adventist Health, but falls under a separate license. The Florida Hospital Cancer Institute (FHCI) was created to coordinate all of the cancer activities in the FH System. Dr. Lee Zehngebot has been leading the clinical activities of the FHCI for over 20 years. Dr. Zehngebot has been the architect of a successful clinical trial within the FHCI. This program has received national awards and recognition. The FHCl's Research department has a strong history of both cooperative group and pharmaceutical trials. Over the last year as we prepared for the transition to a CCOP program, FHCI enrolled CCOP credit equivalents of 56 treatment credits and 54.8 cancer control credits, with the majority of credits accrued since January 2011. In addition, FHCl's catchment area includes counties with over 40% Hispanic population and 20 % African American. While the tumor registry data only shows 11 % Hispanic and 8.5 % African American, enrollment to clinical trials shows 13% Hispanic and 10% African American. The above six hospitals in the FH System along with another MMC wish to become a CCOP. We view a CCOP award as a cornerstone to further integrate our cancer clinical trials and research programs. A CCOP award will allow FHCI to expand its clinical trials efforts in both geography and scope in the central Florida community.